This may be of great importance in terms of the development of hormone-dependent cancers, especially those with the expression of estrogen receptors (e.g., breast, prostate, ovarian cancers), because these compounds may compete with 17-β-estradiol for the binding site of estrogen receptors [4,5]. Here, ESR1 is linked to ovarian cancer.